BackTable Urology

@_backtableUro @CatherineSNamMD @SMSNA_ORG @SSMR_malefactor @UMichUrology bravo

Vasectomy practice is evolving - what do the new AUA guidelines recommend? This week, Dr. Akanksha Mehta joins @CatherineSNamMD to review key updates shaping vasectomy practice #URO294 @SMSNA_ORG @SSMR_malefactor na2.hubs.ly/H04mwJM0

Male LUTS requires more than a prostate-focused approach. In this collaboration with @SUFUorg, @PelvicMedicine and @CraigComiter join Dr. Chris Tenggardjaja for a case-based discussion emphasizing a bladder-and-outlet framework - not just the prostate #URO293 na2.hubs.ly/H04bCnw0

What does the future of biomarker-driven bladder cancer management look like? Dr. Carissa Chu outlines where genomic classifiers are headed next, discussing ongoing trials that integrate molecular subtypes into decision-making and the growing role of ctDNA as a complementary tool across disease stages. Watch the full episode here: youtube.com/watch?v=i_l5Ek… This content is sponsored by Veracyte. #URO280 #UrologicOncology #BladderCancer #Biomarkers #GenomicClassifiers #PrecisionMedicine

Worth listening. #Peduro #trauma is not rare but often underrepresented in #guidelines. It can have severe long-term consequences if not managed appropriately. The #Peduro @Uroweb Guidelines provide evidence-based recommendations specifically for children and adolescents.

How should we approach emergency pediatric genitourinary trauma? This week, @tpagman joins Dr. Arthi Hannallah and Dr. Niccolo Passoni to discuss renal, bladder, urethral, and genital trauma in children, from ED management to follow-up care #URO292 na2.hubs.ly/H041-5h0

How do genetic classifiers actually fit into everyday clinical practice? Dr. Carissa Chu walks through the practical steps of integrating genomic classifiers into clinical workflows, highlighting how results may inform perioperative and future adjuvant decision-making. Watch the full episode here: youtube.com/watch?v=i_l5Ek… This content is sponsored by Veracyte. #URO280 #UrologicOncology #BladderCancer #Biomarkers #GenomicClassifiers #PrecisionMedicine

What’s new in the 2025 AUA guidelines for chronic male pelvic pain? @smacdonald_md and @_KochDoc break down evaluation, multimodal management & avoiding unnecessary antibiotics on the @_backtableUro podcast. 🎙️ Listen here: open.spotify.com/episode/3xBuA6…

What does precision medicine look like beyond gene expression alone? Dr. Carissa Chu examines how additional biomarkers, such as DNA damage repair mutations and ctDNA, may complement genomic classifiers across earlier disease stages. Watch the full episode here: youtube.com/watch?v=i_l5Ek… This content is sponsored by Veracyte. #URO280 #UrologicOncology #BladderCancer #Biomarkers #GenomicClassifiers #PrecisionMedicine

Two specialties, one goal: better care for pelvic floor disorders. In this episode, Dr. Amy Park and Dr. Mark Hoffman sit down with Cleveland Clinic experts Dr. Shannon Wallace (@DrShanWallace) and Dr. Anna Spivak (@annaspivs) to dive into: 🔹 Diagnosing & treating complex colorectal & urogynecological conditions 🔹 Why a multidisciplinary approach makes all the difference 🔹 How pelvic floor therapies support recovery Tune in to hear the full conversation and learn how collaboration improves patient outcomes! Now streaming: na2.hubs.ly/H03W5SC0 #OBGYN107 #pelvicfloordisorders

What do the 2025 @AmerUrological guidelines change about managing male chronic pelvic pain? This week, @smacdonald_md and @_KochDoc break down these new guidelines, from evaluation and multimodal management to avoiding unnecessary antibiotics #URO291 na2.hubs.ly/H03Tn9Y0

How should biomarkers be integrated into NMIBC surveillance strategies? Dr. Sarah Psutka, Dr. Katie Murray, and Dr. Vignesh Packiam highlight the state of biomarkers in the surveillance setting, emphasizing that most tools are not yet practice-changing for routine use. They highlight current adjuncts like blue light cystoscopy, where biomarkers may eventually complement surveillance, and why timing, patient goals, and cost-effectiveness remain central to decisions about escalation of care. Watch the full episode here: youtube.com/watch?v=TqFBZo… This content is sponsored by Ferring Pharmaceuticals. #URO271 #UrologicOncology #BladderCancer #NMIBC #Biomarkers #Cystoscopy #Surveillance

Can genomic classifiers guide treatment sequencing in bladder cancer? Dr. Carissa Chu discusses how genomic classifiers may help navigate increasingly complex treatment decisions in bladder cancer, from selecting intravesical agents after BCG failure to identifying tumors most likely to benefit from neoadjuvant systemic therapy. Watch the full episode here: youtube.com/watch?v=i_l5Ek… This content is sponsored by Veracyte. #URO280 #UrologicOncology #BladderCancer #Biomarkers #GenomicClassifiers #PrecisionMedicine

Our new CME activity on Intermediate-Risk NMIBC is now available on FreeCME! This 2-hour online program covers: - Risk stratification & diagnostic optimization - BCG-refractory management strategies - Multidisciplinary treatment planning - And More Access the activity now on FreeCME: na2.hubs.ly/H03PCSK0 #NMIBC #BladderCancer #Urology #UroOnc #CME

Getting comfortable in urology takes curiosity, repetition, and the right resources. Meredith Donahue, NP and Brynn Moore, RN reflect with Dr. Ruchika Talwar on advice for NPs and nurses entering urology and urologic oncology. They highlight learning the why behind intravesical therapy through resources like the American Urological Association (AUA) Core Curriculum, tumor boards, hands-on catheter experience, and patient-centered tools from Bladder Cancer Advocacy Network (BCAN). Watch the full episode here: youtu.be/-qi7WfFDrlc?si… This content is sponsored by Ferring Pharmaceuticals. #URO273 #Urology #UrologicOncology #BladderCancer #NMIBC

A new @NEJM piece highlights how EV + pembro is reshaping urothelial cancer care. Check out our latest episode exploring what these responses mean and the growing interest in consolidative surgery ⬇️ open.spotify.com/episode/003Uq4… #URO290 @UroOnc @abhinav__khanna @DSRoberson93 @MayoUrology

What do you do when metastatic urothelial cancer has a dramatic response to systemic therapy? This week, @abhinav__khanna and @DSRoberson93 discuss consolidative cystectomy and the evolving role of surgery in advanced disease #URO290 na2.hubs.ly/H03M8nW0

Can urinary biomarkers safely reduce the reliance on cystoscopy? Dr. Sarah Psutka, Dr. Katie Murray, and Dr. Vignesh Packiam explore how emerging urine-based biomarkers can play a role in screening patients with microscopic and gross hematuria. They examine the patient populations where de-intensification may be feasible and why cystoscopy remains the gold standard. Watch the full episode here: youtube.com/watch?v=TqFBZo… This content is sponsored by Ferring Pharmaceuticals. #URO271 #UrologicOncology #BladderCancer #NMIBC #Biomarkers #Cystoscopy #Hematuria

Can molecular subtypes refine risk beyond traditional staging? Dr. Carissa Chu discusses how molecular subtypes capture biologic heterogeneity, offering additional context for risk stratification and patient counseling in bladder cancer. Watch the full episode here: youtube.com/watch?v=i_l5Ek… This content is sponsored by Veracyte. #URO280 #UrologicOncology #BladderCancer #Biomarkers #GenomicClassifiers #PrecisionMedicine

Delivering intravesical therapy at scale requires intention and teamwork. Meredith Donahue, NP and Brynn Moore, RN share their perspectives with Dr. Ruchika Talwar on the logistical realities of running a high-volume intravesical therapy clinic. They discuss workflow design, pharmacy coordination, continuity of care, and why condensing treatment days can improve both efficiency and the patient experience. Watch the full episode here: youtu.be/-qi7WfFDrlc?si… This content is sponsored by Ferring Pharmaceuticals. #URO273 #Urology #UrologicOncology #BladderCancer #NMIBC